Keebles advises on BresMed acquisition by leading US private equity investor
Keebles have advised on the successful acquisition. BresMed Health Solutions by US-based Arsenal Capital Partners.
Keebles’ Corporate team, led by Michael Hall, provided legal advice to BresMed during the process. Rory Conwill and Peter Turk supported Michael
Michael Hall, Partner at Keebles, said. “We are thrilled to have advised BresMed. Which is another demonstration of the global standing of some of the fantastic businesses based in the region.
Sheffield-based BresMed Health Solutions, a pioneer in providing health economic research, communications, and consulting services to the global pharmaceutical industry, has been acquired by Arsenal Capital Partners. A leading US private equity firm that invests in healthcare and specialty industrials companies.
The acquisition of BresMed is the first in a series of investments by Arsenal to form a new value demonstration company in the market access, health economics and outcomes research, patient preference, and real world evidence space that will transform the way medical advances reach the patients who need them.
The new company will support biopharmaceutical clients with the strategy, evidence and communication tools to help maximize the value of their products. Guiding healthcare stakeholders worldwide in difficult decisions about resource allocation and access to new therapies.
“We look forward to seeing Arsenal and BresMed take the all-important next steps in developing this new platform. We wish Nic and the BresMed team well in this exciting journey.”
Nic Brereton, BresMed’s CEO and founder, who will continue to lead BresMed, said. “We are proud of the company that we have created. After dozens of discussions, Arsenal stood out as the best partner for BresMed.
“Arsenal shares our bold vision for the future, has a deep understanding of the space, and has strong cultural alignment. I am confident that in partnership with our clients we will have a transformational impact on the speed, efficiency and quality of evidence required to support industry decision making.”